The last studies noticed that the pattern of B7H4 expression in RCC could be modulated by tyrosine kinase inhibitors (TKIs) and mTOR inhibitors combined with immunotherapy to improve the response rate in patients. Here, MTOR is linked to renal cell carcinoma.